Skip to content

Immix Biopharma, Inc. IMMX Total Operating Expenses

Total Operating Expenses at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
$46.09M-29.3%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$41.37M-12.7%
Xencor logo
XencorXNCR
$82.38M+8.5%
Immunome logo
ImmunomeIMNM
$59.33M+24.7%
Precigen logo
PrecigenPGEN
$29.25M+22.2%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$24.43M+10.2%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s total operating expenses?
Immix Biopharma, Inc. (IMMX) reported total operating expenses of $10.8M in Q1 2026.
How has Immix Biopharma, Inc.'s total operating expenses changed year-over-year?
Immix Biopharma, Inc.'s total operating expenses increased by 130.7% year-over-year, from $4.68M to $10.8M.
What is the long-term trend for Immix Biopharma, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s total operating expenses has grown at a 117.0% compound annual growth rate (CAGR), from $1.35M to $29.96M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.